nature research

Corresponding author(s):	Professor Huifang Shang
Last updated by author(s):	YYYY-MM-DD

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

C.			
\ta	ŤΙ	ICT I	2

For	all statistical ar	nalyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.	
n/a	Confirmed		
	The exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement	
	A stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly	
	The statis	tical test(s) used AND whether they are one- or two-sided non tests should be described solely by name; describe more complex techniques in the Methods section.	
	A descript	tion of all covariates tested	
\boxtimes	A descript	tion of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons	
\boxtimes	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)		
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give P values as exact values whenever suitable.		
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings		
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes		
\square Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated			
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.	
So	ftware an	d code	
Poli	cy information	about <u>availability of computer code</u>	
Da	ata collection	(NA	
Da	ata analysis	SPSS	
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.			

Data

Policy information about <u>availability of data</u>

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Anonymized data can be obtained upon request from qualified investigators to replicate procedures and results.

Field-spe	ific reporting	
Please select the or	pelow that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.	
∑ Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences	
For a reference copy of t	locument with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>	
Life scier	es study design	
All studies must dis	se on these points even when the disclosure is negative.	
Sample size		
Data exclusions		
Replication		
Randomization		
Blinding		
Reportin	for specific materials, systems and methods	
	rom authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,	
system or method list	is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.	
Materials & experimental systems Methods		
n/a Involved in th		
Antibodies Antibodies Eukaryotic	ChIP-seq Iines Flow cytometry	
	and archaeology MRI-based neuroimaging	
	ther organisms	
Clinical data		
Dual use re	arch of concern	
Human rese	ch participants	
	out <u>studies involving human research participants</u>	
Population chara	In this ongoing prospective longitudinal cohort study performed at the Department of Neurology, Sichuan University West China Hospital, we aimed to investigate the prognosis and progression of PD in southwest China.	
Recruitment	This project was initiated in February 2014 and aimed to recruit patients with early PD (n=302). PD was diagnosed based on the United Kingdom PD Society Brain Bank clinical diagnostic criteria 12. All subjects recruited at baseline had a disease duration of <3 years. The exclusion criteria were as follows: (1) patients with cognitive impairment, as assessed by the Beijing version of the Montreal Cognitive Assessment (MOCA) tool with a cut-off score <22 13, (2) patients with motor fluctuations and dyskinesia, as scored ≥1 on the Unified Parkinson's Disease Rating Scale (UPDRS) part IV, and (3) patients with Hoehn and Yahr (H&Y) stage ≥3.	
Ethics oversight	The study was approved by the Ethics Committee of Sichuan University West China Hospital and written informed consent	

Note that full information on the approval of the study protocol must also be provided in the manuscript.

was obtained from all participants.

Dual use research of concern

Policy information about <u>dual use research of concern</u>

Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

		Э
	$\overline{}$	ı
	Ξ	ט
	זכם	ļ
	۷,	
	Ξ	3
	C,	D
	7	2
	ŗ.	2
	Ų	2
	\cap	D
	a	b
	=	ξ
	^	۶
	ומטמוכו	4
		כ
Ξ		
	$\overline{}$	3
	ิด	Б
	7	5
	7	5
	$\frac{1}{2}$	כ כ
	$\frac{1}{2}$	כ כ
		כ כ
		כ כ
		כ כ

=	
⋞	
Ę	
È	Ś

No	Yes	
\boxtimes		Public health
\boxtimes		National security
\boxtimes		Crops and/or livestock
\boxtimes		Ecosystems
\boxtimes		Any other significant area
xne	rim	ents of concern

Experiments of concern

Does the work involve any of these experiments of concern:

N٥	Yes
\times	Demonstrate how to render a vaccine ineffective
\times	Confer resistance to therapeutically useful antibiotics or antiviral agents
X	Enhance the virulence of a pathogen or render a nonpathogen virulent
\times	Increase transmissibility of a pathogen
\times	Alter the host range of a pathogen
\times	Enable evasion of diagnostic/detection modalities
X	Enable the weaponization of a biological agent or toxin
\times	Any other potentially harmful combination of experiments and agents